Expression of p53 in human leukemia and lymphoma
M Prokocimer, M Shaklai, HB Bassat, D Wolf, N Goldfinger and V Rotter
Analysis of fresh human tumors have indicated that patients with B type
lymphoproliferative diseases and the majority of patients with acute
lymphoblastic leukemia (ALL) express elevated levels of p53 production. It
is suggested that in these human malignancies, p53 may provide a novel tool
for monitoring cancer activity. Conversely, p53 is not expressed in acute
myeloid leukemias, myeloproliferative diseases, or myeloid leukemic cell
lines. Analysis of the p53 gene structure indicated the existence of
similar patterns of p53 restriction fragments in producer and nonproducer
cells, which suggests that the p53 gene is not altered in the latter.
However, in one case of acute promyelocytic leukemia (APL), we have
observed a rearrangement in the p53 gene. Karyotype analysis has indicated
that these APL cells do not contain the typical 15;17 translocation. In
other APL patients who exhibit a 15;17 translocation, we found no genomic
changes of the p53, suggesting that the p53 gene, which was recently mapped
to the short arm of chromosome 17 in the human, is not structurally related
to the typical chromosomal break point found in the long arm of chromosome
17 of APL patients.
Volume 68,
Issue 1,
pp. 113-118,
07/01/1986
Copyright © 1986 by The American Society of Hematology
